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21.6% pt in normal troponin T group had poor outcome (P value
0.0146). After 30 days follow up 50% pt died in elevared troponin
group while only 13.5% pt died in normal troponin group (P value
0.0389).
Conclusion: In patients of acute ischemic stroke with raised
troponin T level there was increased morbidity (P value 0.0146)
and mortality (P value 0.0146) which was found to be statistically
significant.
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Background: Although warfarin has been extensively studied in
clinical trials, little is known about rates of hemorrhage attribut-
able to its use in routine clinical practice. Our objective was to
examine incident hemorrhagic events in a municipal hospital
based cohort of patients with atrial fibrillation who were started
treatment with warfarin.
Methods: We conducted a municipal hospital based cohort study
involving patients (age  50 yr) with atrial fibrillation who started
taking warfarin between Jan 2013, and March 2014. We defined a
major hemorrhage as any visit to hospital for hemorrage. We
determined crude rates of hemorrhage duringwarfarin treatment,
overall and stratified by CHADS 2 score (congestive heart failure,
hypertension, age  75 yr, diabetes mellitus and prior stroke,
transient ischemic attack or thromboembolism).
Results: We included 469 patients with atrial fibrillation who
started treatment with warfarin during the study period. Overall,
the rate of hemorrhage was 3.5% (95% confidence interval [CI]
3.8%e3.9%) per person-year. The risk of major hemorrhage was
highest during the first 30 days of treatment. During this period,
rates of hemorrhage were 11.6% (95% CI 11.1%e12.5%) per person-
year in all patients and 15.6% (95% CI 14.3%e19.4%) per person-
year among patients with a CHADS 2 scores of 4 or greater. Over
the 13months follow-up, 38 patients (8.1%) visited the hospital for
hemorrhage; of these patients, 2 (5%) died in hospital.
Conclusions: In this municipal hospital based cohort of older pa-
tients with atrial fibrillation, we found that rates of hemorrhage
are highest within the first 30 days of warfarin therapy. These
rates are considerably higher than the rates of 1%e3% reported in
randomized controlled trials of warfarin therapy. Our study pro-
vides timely estimates of warfarin-related adverse events that
may be useful to clinicians, patients and policy-makers as new
options for treatment become available.
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Background: It is said pulmonary embolism is “a great imitator”. It
can present with different characteristics which can vary from
patient to patient in young vs elderly patients. Pulmonary embo-
lism (PE) is a blockage of the main pulmonary artery or one of its
branches by a substance that has travelled from elsewhere in the
body through the bloodstream. PE most commonly results from
deep vein thrombosis.
Symptoms of pulmonary embolism include dyspnea, tachy-
cardia, tachypnea, chest pain, palpiations, cyanosis, hypotension,
and sudden death. Diagnosis is based on these clinical findings
and imaging studies, usually CT pulmonary angiography. Treat-
ment is typically with anticoagulation. Severe cases may require
thrombolysis or may require catheter based intervention via
pulmonary thrombectomy.
Objective: The purpose of this study is to assess frequency, risk
factors, presenting symptoms, treatment, complications and In-
hospital outcomes of pulmonary embolism in young patients
compared with those of elderly patients.
Methods: We studied 18 patients of pulmonary embolism in < 40
years age group and 20 patients age more than 40 years admitted
in our hospital from August 2012 to July 2014.Patients with a
diagnosis of pulmonary embolism admitted to between January
2012 and January 2014 were included in this study. A diagnosis of
pulmonary embolsim was based on: chest pain, electrocardio-
graphic changes 2 D ECHO, D dimer, and typical time related
pattern of ABG, ECG, CT Pulmonary angiography and response to
treatment.
Results: Breathlessness was the most common presentation in 30
patients (78.92%), while chest pain in 6 patients(15.2%) and hy-
potension in 2 patients(5.7%). Incidence ofpulmonary embolism is
exceedingly higher inmales (78.92%) compared to females.Typical
symptoms seen in 70%.Risk factors such as prolonged bed rest,
immobilisation levels are more common in elderly patient-
s,whereas family history (22.10%) and diabetes(11.59%) are less
frequent.Prevalence of chest pain is almost same in younger
(76.81%) and elderly(78.6%) age group,most common sign being
tachypnea .74.25% of young patients with pulmonary embolism
received treatment in form of thrombolysis, most of the patiens
(85%) received streotokinase ,15% patients received tenectaplace.
4 patients received intrapulmonary thrombolysis with guidance
of catheter in PA.
Total 5 patients died, most of due to refractory hypotension .2
patients developed chronic pulmonary thromboembolism.
Elevated serum homocysteine levels are seen in 28(10.14%) of
young patients.Primary thrombolysis had good outcome in < 40
years age group.Postprocedure complications are almost negli-
gible ( < 3%) in young age group.The incidence of in-hospital
congestive heart failure, and major bleeding were lowest(<2%) in
the youngest age group.
Conclusion: Younger patients have better outcome as compared
to elderly patients.
Tenectaplase in postoperative acute pulmonary
thromboembolism
S. Thrudeep, S. Gagan, G. Geofi, G. Rupesh, G. Rajesh,
T.G. Jayakumar, S. Abdul Khadar
Department of Cardiology, Amala Institute of Medical Sciences,
Thrissur, India
Background: The Incidence of Acute pulmonary thromboembo-
lism, as one of the post operative fatal complications, is around
1.6%. Management of embolism in postoperative cases is always
difficult and thus leading onto high rates of mortality and poor
prognosis. According to ESC guidelines, the use of Tenectaplase is
an important determining factor in the prognosis and
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management, with absolute contraindication for early post
operative cases ie. within 3 weeks. No large randomized trials
have been reported in postoperative cases of pulmonary throm-
boembolism till date.
Aim: This retrospective study was aimed to evaluate the use of
Tenectaplase in postoperative cases of acute pulmonary
thromboembolism.
Methods: Ten post operative cases of acute pulmonary thrombo-
embolism, confirmed by CT pulmonary angiography, in which
Tenectaplase (Velix) was the drug of choice for thrombolysis were
selected (with their high risk consent). Electrocardiography, RV
dysfunction by 2D echocardiography and clinical conditions such
as tachypnea, hypotension and oxygen saturation were measured
and analyzed statistically.
Results: Initially all patients were tachypneic of which 50% had
hypotension and 9/10 had hypoxia. Thrombolytic treatment with
single intravenous bolus of Tenectaplase (30/40 mg) could signif-
icantly (p < 0.0001) improve RV function. Improvement in hypo-
tension was observed in 3/5 cases, whereas 1/9 failed to improve
hypoxia. Only 1/10 case expired due to intracranial heamorhage
immediately after thrombolysis. In one case, Tenectaplase was
given intra-arterial but the patient died after few days after IC
bleed.
Conclusion: Early diagnosis and treatment of pulmonary embo-
lism with potent thrombolytics can be life saving. Though this
study was conducted in small sample population for a short
duration the result of this study concluded that Tenectaplase can
be a potent thrombolytic agent which can be used as drug of
choice in postoperative cases of acute pulmonary thromboem-
bolism with high consent. But its potential complication and risk
factors should be managed promptly.
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Background: Temporal dispersion of electrical instability events
and hemodynamically significant arrhythmias in myocardial
infarction (MI) after thrombolysis is not fully established.
Methods: Temporal dispersion of electrical instability events and
hemodynamically significant arrhythmias was assessed using 24
hour holter recording in 200 patients of myocardial infarction (MI)
presenting within 2 hours.
Results: Anterior wall MI had higher incidence of nonsustained
ventricular tachycardia and ventricular ectopy with marked
decrease in beat to beat (BB) variability, predisposing this group for
malignant arrhythmias. Inferior wall MI showed more bradyar-
rhythmic events and higher BB variability (P value<0.05). Electrical
instability after MI predominates in the first 8-10 hours (P value
<0.05) and tends to subside thereafter.
Ventricular ectopy, tachyarrhythmia events, bradyarrhythmia
and beat to beat variability in myocardial infarction during first 24
hour of presentation.
Conclusions: Despite the burgeoning increase in the number of MI
patients in coronary care units, vigilant monitoring is recom-
mended at least during this vulnerable period.
Characteristics AWMI (n¼86) IWMI (n-95) LWMI (n¼27)
Total Burden of hemodynamic significant tachyarrhythmia 7 (8.5%) 6 (7.6%) 2 (7.7%)
1st quartile(0-6 hr) (% of total tachyarrhythmia episode) 78% 82% 84%
2nd quartile(7-12 hr) (% of total tachyarrhythmia episode) 13% 12% 12%
3rd quartile(13-18 hr) (% of total tachyarrhythmia episode) 5% 3% 3%
4th quartile(19-24hr) (% of total tachyarrhythmia episode) 4% 3% 1%
Nonsustained VT 51 (62) 50 (57) 12 (46)
Sustained VT 8 (9.3%) 5 (5.2%) 1 (3.8%)
Ventricular fibrillation 3 (3.6%) 3 (3.3%) 1 (3.8%)
Time to onset of 1st hemodynamic significant arrhythmia
SVT/VT/VF/polymorphic VT
2.2±1.1hr 2.6±1.2 2.6±1.3hr
Burden of VE in 24 hr (% of total RR complexes)$ 13% 3.2% 2.6%
Burden of VE in 1st quartile(0-6 hr) (% of total VE) 61% 64% 73%
Burden of VE in 2nd quartile(7-12 hr) (% of total VE) 31% 28% 23%
Burden of VE in 3rd quartile(13-18 hr) (% of total VE) 5% 6% 4%
Burden of VE in 4th quartile(19-24hr) (% of total VE) 3% 2% 0%
Number of patients with bradyarrhythmia 5(6.1) 19(20.6) 1(3.8)
Bradycardia burden (bradycardia complexes as % of total RR
complexes)
1st quartile(0-6 hr) - 56 22
2nd quartile(7-12 hr) - 32 8
3rd quartile(13-18 hr) - 18 3
4th quartile(19-24hr) - 6 3
Beat to Beat RR variability(% RR>50) 7.2% 22.3% 14.8%
Beat to Beat RR variability(Magid SD) in milliseconds 40±8 50±36 54±11
Beat to Beat RR variability(Kleiger SD) in milliseconds 49±9 83±25 56±18
Beat to Beat RR variability(RMS-SD) in milliseconds 22±7 82±10 28±12
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